Julie Johnson, APRN
Nurse Practitioner · Douglas, WYNPI 1154912012
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AstraZeneca at 24.3% of the total.
Across 44 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$185
- Lilly USA, LLC$111
- Novo Nordisk$106
- Novartis$86
- Sanofi-aventis U.S. LLC$84
- Amgen$55
- plus $133 from 6 others
What the payments were for
- Food & beverage$760100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $185 |
| Lilly USA, LLC | 8 | $111 |
| Novo Nordisk | 5 | $106 |
| Novartis | 5 | $86 |
| Sanofi-aventis U.S. LLC | 5 | $84 |
| Amgen | 4 | $55 |
| Medline Industries LP | 2 | $37 |
| GSK | 2 | $29 |
| Boston Scientific | 1 | $22 |
| Optinose US, Inc. | 1 | $17 |
| Organon | 1 | $14 |
| Merck | 1 | $14 |
How this compares
$760 in reported general payments places this provider in the 85th percentile of 150 nurse practitioner providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 167 | $176,464 |
| MounjaroTirzepatide | 104 | $108,929 |
| OzempicSemaglutide | 74 | $76,458 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $59,932 |
| FarxigaDapagliflozin Propanediol | 46 | $56,833 |
| TrulicityDulaglutide | 39 | $49,459 |
| JardianceEmpagliflozin | 47 | $46,869 |
| JanuviaSitagliptin Phosphate | 36 | $33,660 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $28,316 |
| XareltoRivaroxaban | 14 | $23,866 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $21,182 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $17,892 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $15,686 |
| EntrestoSacubitril/Valsartan | 11 | $14,347 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $13,074 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $111 | $158,388143 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $29 | $95,233132 claims |
| Novo NordiskOzempic | $106 | $76,45874 claims |
| AstraZenecaFarxiga, Symbicort | $185 | $62,96864 claims |
| MerckJanuvia, Belsomra | $14 | $44,92353 claims |
| NovartisEntresto | $86 | $14,34711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 150 nurse practitioner providers in Wyoming.
Other nurse practitioner in Douglas
- Esther Gilman-KehrerLaramie$32K
- Kerry CarrJackson$19K
- Jessica RodriguezLaramie$17K
- Elizabeth DannewaldJackson$5K
- Kristin BrittCasper$5K
- Kerry FischerCasper$4K
- Molly RodrickCasper$3K
- Nichole TaylorGillette$3K
- Janine GloverCasper$3K
- Amy GruwellCasper$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.